PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
17876342-0	2008	PXR, CAR and HNF4alpha genotypes and their association with pharmacokinetics and pharmacodynamics of docetaxel and doxorubicin in Asian patients.	Docetaxel	101-110	nuclear receptor subfamily 1 group I member 2	Homo sapiens	0-3	
20041327-7	2010	RESULTS: Our study showed that vincristine, tamoxifen, vinblastine, docetaxel, cyclophosphamide, flutamide, ifosfamide and paclitaxel activate PXR-mediated Pgp induction, and were additionally shown to affect the intracellular accumulation of the Pgp probe rhodamine 123.	Docetaxel	68-77	nuclear receptor subfamily 1 group I member 2	Homo sapiens	143-146	
24193570-0	2014	Pharmacogenetic effects of regulatory nuclear receptors (PXR, CAR, RXRalpha and HNF4alpha) on docetaxel disposition in Chinese nasopharyngeal cancer patients.	Docetaxel	94-103	nuclear receptor subfamily 1 group I member 2	Homo sapiens	57-60	
24193570-1	2014	PURPOSE: This exploratory study was aimed at elucidating the pharmacogenetics of regulatory nuclear receptors (PXR, CAR, RXRalpha and HNF4alpha) and their implications on docetaxel pharmacokinetics and pharmacodynamics in local Chinese nasopharyngeal cancer patients.	Docetaxel	171-180	nuclear receptor subfamily 1 group I member 2	Homo sapiens	111-114	
18839173-7	2009	RESULTS: Paclitaxel, erlotinib, tamoxifen, ifosfamide, flutamide and docetaxel are able to activate PXR, while only strong PXR activation leads to significant induction of CYP3A4 activity.	Docetaxel	69-78	nuclear receptor subfamily 1 group I member 2	Homo sapiens	100-103	
17876342-8	2008	The PXR-24381A>C variants were significantly more common in Indians compared to Chinese or Malays (32/18/21%, P=0.035) Inter-individual and inter-ethnic variations of docetaxel and doxorubicin pharmacokinetics or pharmacodynamics exist, but genotypic variability of the transcriptional regulators PAR, CAR and HNF4alpha cannot account for this variability.	Docetaxel	170-179	nuclear receptor subfamily 1 group I member 2	Homo sapiens	4-7	
34733941-0	2021	Curcuma zedoaria petroleum ether extract reverses the resistance of triple-negative breast cancer to docetaxel via pregnane X receptor.	Docetaxel	101-110	nuclear receptor subfamily 1 group I member 2	Homo sapiens	115-134	
34733941-14	2021	Conclusions: Our research showed that PECZ reversed docetaxel resistance in TNBC by PXR both in vitro and in vivo, which provides the basis for further investigations into the potential therapeutic impact of docetaxel resistance in TNBC.	Docetaxel	52-61	nuclear receptor subfamily 1 group I member 2	Homo sapiens	84-87	
34733941-14	2021	Conclusions: Our research showed that PECZ reversed docetaxel resistance in TNBC by PXR both in vitro and in vivo, which provides the basis for further investigations into the potential therapeutic impact of docetaxel resistance in TNBC.	Docetaxel	208-217	nuclear receptor subfamily 1 group I member 2	Homo sapiens	84-87	
15175893-6	2004	Furthermore, employing cell-based reporter gene assay in CV-1 cells, we evaluated the capacity of paclitaxel and docetaxel to activate human pregnane X receptor (hPXR), an orphan nuclear receptor that plays a key role in the transcriptional regulation of CYP3A4.	Docetaxel	113-122	nuclear receptor subfamily 1 group I member 2	Homo sapiens	141-160	
11329060-5	2001	Docetaxel"s silent properties reflect its inability to displace transcriptional corepressors from SXR.	Docetaxel	0-9	nuclear receptor subfamily 1 group I member 2	Homo sapiens	98-101